216 related articles for article (PubMed ID: 23548265)
1. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Kryeziu K; Jungwirth U; Hoda MA; Ferk F; Knasmüller S; Karnthaler-Benbakka C; Kowol CR; Berger W; Heffeter P
Mol Cancer Ther; 2013 Jun; 12(6):1073-84. PubMed ID: 23548265
[TBL] [Abstract][Full Text] [Related]
2. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Liu ZM; Tseng HY; Cheng YL; Yeh BW; Wu WJ; Huang HS
Toxicol Appl Pharmacol; 2015 May; 285(1):41-50. PubMed ID: 25791921
[TBL] [Abstract][Full Text] [Related]
3. Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
Mesbahi Y; Zekri A; Ahmadian S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Eur J Pharmacol; 2018 Feb; 820():274-285. PubMed ID: 29274334
[TBL] [Abstract][Full Text] [Related]
4. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
Boyko-Fabian M; Niehr F; Distel L; Budach V; Tinhofer I
PLoS One; 2014; 9(6):e98867. PubMed ID: 24927258
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
6. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Liu ZM; Tseng JT; Hong DY; Huang HS
Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Lam SK; Li YY; Zheng CY; Ho JC
Int J Oncol; 2015 Jan; 46(1):113-22. PubMed ID: 25335113
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
9. Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways.
Mandegary A; Torshabi M; Seyedabadi M; Amirheidari B; Sharif E; Ghahremani MH
Biomed Res Int; 2013; 2013():237543. PubMed ID: 24312908
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin.
Chiu HW; Ho YS; Wang YJ
J Mol Med (Berl); 2011 Sep; 89(9):927-41. PubMed ID: 21594580
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.
Guilbert C; Annis MG; Dong Z; Siegel PM; Miller WH; Mann KK
PLoS One; 2013; 8(12):e85995. PubMed ID: 24392034
[TBL] [Abstract][Full Text] [Related]
12. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
Kriegs M; Kasten-Pisula U; Rieckmann T; Holst K; Saker J; Dahm-Daphi J; Dikomey E
DNA Repair (Amst); 2010 Aug; 9(8):889-97. PubMed ID: 20615764
[TBL] [Abstract][Full Text] [Related]
13. PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
Luo Q; Li Y; Deng J; Zhang Z
Chem Biol Interact; 2015 Jan; 226():12-22. PubMed ID: 25499136
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.
Li L; Wang H; Yang ES; Arteaga CL; Xia F
Cancer Res; 2008 Nov; 68(22):9141-6. PubMed ID: 19010885
[TBL] [Abstract][Full Text] [Related]
15. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
16. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
17. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Lang M; Wang X; Wang H; Dong J; Lan C; Hao J; Huang C; Li X; Yu M; Yang Y; Yang S; Ren H
Cancer Lett; 2016 Aug; 378(2):87-96. PubMed ID: 27212442
[TBL] [Abstract][Full Text] [Related]
19. SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells.
Kodigepalli KM; Dutta PS; Bauckman KA; Nanjundan M
FEBS Lett; 2013 Jan; 587(1):5-16. PubMed ID: 23178716
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
